Literature DB >> 24753359

Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma.

Ling Deng1, Yan Li, Ping Ai, Yuxin Xie, Hong Zhu, Nianyong Chen.   

Abstract

Recent studies have suggested that the action of IkappaB kinase alpha (IKKα) as a tumor suppressor is crucial in the development of skin carcinoma, but its role in nasopharyngeal carcinoma (NPC) remains unknown. We examined the IKKα expression in specimens from 157 NPC patients by immunohistochemistry and analyzed the effect of IKKα on prognosis. The functional significance of IKKα expression in NPC cell lines was investigated by IKKα overexpression or downregulation in in vitro studies. The in vitro assays revealed that the IKKα expression was negatively correlated with the invasiveness, migration, and angiogenesis of NPC cells. Overexpression or downregulation of IKKα could significantly repress or enhance the above characteristics, respectively, and these effects were independent of IKKα kinase or EBNA1. In 157 NPC cases, IKKα was differentially expressed in NPC tissues. High expression of IKKα was associated significantly with a high disease-free survival (DFS; P = 0.002) or overall survival (OS; P = 0.014). Multivariate analyses showed that the IKKα expression was an independent risk factor for DFS (HR, 2.302; P = 0.011) and OS (HR, 3.578; P = 0.006). Our findings indicated that IKKα plays a crucial role as a tumor suppressor that suppresses the invasion, metastasis, and angiogenesis of NPC cells in vitro and correlates with the survival in NPC patients. Therefore, IKKα is not only a novel independent prognostic indicator in NPC, but also targeting IKKα expression may provide a potential therapeutic strategy for NPC.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  IkappaB kinase alpha; nasopharyngeal carcinoma; prognostic marker; tumor malignant behaviors; tumor suppressor

Mesh:

Substances:

Year:  2013        PMID: 24753359     DOI: 10.1002/mc.22087

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

1.  IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy.

Authors:  X Fang; J-H Jeong; X Long; S-J Park; D Wang; M Shuai; R Wei; C Li; S Li; S Zhang; M B Duran; K-W Lo; S W Tsao; R Glaser; Z Luo; X Feng; Y Tian; J-L Luo
Journal:  Cell Death Differ       Date:  2016-04-08       Impact factor: 15.828

2.  Opposed expression of IKKα: loss in keratinizing carcinomas and gain in non-keratinizing carcinomas.

Authors:  Desheng Xiao; Jiantao Jia; Ying Shi; Chunyan Fu; Ling Chen; Yiqun Jiang; Li Zhou; Shuang Liu; Yongguang Tao
Journal:  Oncotarget       Date:  2015-09-22

3.  Apigenin blocks IKKα activation and suppresses prostate cancer progression.

Authors:  Sanjeev Shukla; Rajnee Kanwal; Eswar Shankar; Manish Datt; Mark R Chance; Pingfu Fu; Gregory T MacLennan; Sanjay Gupta
Journal:  Oncotarget       Date:  2015-10-13

4.  Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.

Authors:  Jian Zang; Chen Li; Man Xu; Wanni Xu; Xiaowei Kang; Jianhua Wang; Shanquan Luo; Mei Shi
Journal:  Sci Rep       Date:  2018-09-06       Impact factor: 4.379

5.  Regulation of epidermal differentiation through KDF1-mediated deubiquitination of IKKα.

Authors:  Yuanyuan Li; Liangfeng Tang; Jiping Yue; Xuewen Gou; Anning Lin; Scott D Weatherbee; Xiaoyang Wu
Journal:  EMBO Rep       Date:  2020-04-01       Impact factor: 8.807

6.  CHUK/IKK-α loss in lung epithelial cells enhances NSCLC growth associated with HIF up-regulation.

Authors:  Evangelia Chavdoula; David M Habiel; Eugenia Roupakia; Georgios S Markopoulos; Eleni Vasilaki; Antonis Kokkalis; Alexander P Polyzos; Haralabia Boleti; Dimitris Thanos; Apostolos Klinakis; Evangelos Kolettas; Kenneth B Marcu
Journal:  Life Sci Alliance       Date:  2019-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.